← All trials
NCT04204096
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 27, 2020
- Primary completion
- Jun 27, 2020
- Completion date
- Nov 27, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1800
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Vaccine InstituteLead sponsor
- Bill and Melinda Gates FoundationCollaborator
- SK Bioscience Co., Ltd.Collaborator
- University of the PhilippinesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.